hrcak mascot   Srce   HID

Pregledni rad

Ovarian Cancer

Eduard Vrdoljak
Tomislav Omrčen
Spomenka Mikuš
Branka Petrić-Miše

Puni tekst: hrvatski, pdf (64 KB) str. 207-210 preuzimanja: 3.991* citiraj
APA 6th Edition
Vrdoljak, E., Omrčen, T., Mikuš, S. i Petrić-Miše, B. (2001). Rak jajnika. Medicus, 10 (2_Maligni tumori), 207-210. Preuzeto s https://hrcak.srce.hr/19777
MLA 8th Edition
Vrdoljak, Eduard, et al. "Rak jajnika." Medicus, vol. 10, br. 2_Maligni tumori, 2001, str. 207-210. https://hrcak.srce.hr/19777. Citirano 10.07.2020.
Chicago 17th Edition
Vrdoljak, Eduard, Tomislav Omrčen, Spomenka Mikuš i Branka Petrić-Miše. "Rak jajnika." Medicus 10, br. 2_Maligni tumori (2001): 207-210. https://hrcak.srce.hr/19777
Harvard
Vrdoljak, E., et al. (2001). 'Rak jajnika', Medicus, 10(2_Maligni tumori), str. 207-210. Preuzeto s: https://hrcak.srce.hr/19777 (Datum pristupa: 10.07.2020.)
Vancouver
Vrdoljak E, Omrčen T, Mikuš S, Petrić-Miše B. Rak jajnika. Medicus [Internet]. 2001 [pristupljeno 10.07.2020.];10(2_Maligni tumori):207-210. Dostupno na: https://hrcak.srce.hr/19777
IEEE
E. Vrdoljak, T. Omrčen, S. Mikuš i B. Petrić-Miše, "Rak jajnika", Medicus, vol.10, br. 2_Maligni tumori, str. 207-210, 2001. [Online]. Dostupno na: https://hrcak.srce.hr/19777. [Citirano: 10.07.2020.]

Sažetak
Ovarian cancer is the main reason of death
among gynecological cancers. There is no routine test for
early diagnosis of ovarian cancer and early detection of this
cancer is difficult because of lack of simptomatology. Overall
survival rate among patients with ovarian cancer is almost
50 % and it represents a significant increase of survival in the
last decade due the introduction of paclitaxel in the treatment
of advanced stages of ovarian carcinoma.

Ključne riječi
ovarian cancer; chemotherapy; paclitaxel; cisplatin

Hrčak ID: 19777

URI
https://hrcak.srce.hr/19777

[hrvatski]

Posjeta: 4.970 *